Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sparsentan in FSGS
NCT01613118Phase 2Completed
- Sponsor
- Travere Therapeutics
- Start
- Mar 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of sparsentan in focal segmental glomerulosclerosis (FSGS), sponsored by Travere Therapeutics. Started Mar 2014; status: completed.
02
Drugs
sparsentan
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT01613118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01613118.